Last updated: October 12, 2026
Cefaclor is a mature, off-patent second-generation cephalosporin with limited commercial growth potential. The U.S. branded product, Ceclor, no longer drives the market. Revenue is concentrated in low-cost generic capsules, oral suspensions and, in some markets, extended-release tablets. Pricing pressure, substitution by newer oral antibiotics and reduced use of broad-spectrum antibiotics constrain long-term growth.
No reliable public source reports cefaclor revenue by manufacturer in the United States. Its financial trajectory is best assessed through regulatory status, generic competition, prescription volume, reimbursement pricing and supply continuity rather than branded sales forecasts.
What is cefaclor and which products contain it?
Cefaclor is an orally administered second-generation cephalosporin used against susceptible bacterial infections. It has activity against selected gram-positive and gram-negative organisms and is marketed in several oral dosage forms.
| Attribute |
Cefaclor profile |
| Active ingredient |
Cefaclor |
| Drug class |
Second-generation cephalosporin |
| Original U.S. brand |
Ceclor |
| Original innovator |
Eli Lilly and Company |
| U.S. first approval |
1979 |
| Administration |
Oral |
| Common dosage forms |
Capsules, oral suspension, extended-release tablets in certain markets |
| Main uses |
Respiratory, ear, skin and urinary tract infections, subject to susceptibility |
| Regulatory category |
Small-molecule prescription antibiotic |
| Current commercial status |
Predominantly generic |
| Biosimilar exposure |
None |
The FDA-approved Ceclor labeling covered capsules and oral suspension. Ceclor CD, an extended-release formulation, was developed to improve dosing convenience but did not create a durable branded market after generic competition expanded.[1]
Cefaclor is not interchangeable with every oral cephalosporin. Prescribers may select cefalexin, cefuroxime, cefpodoxime or amoxicillin-clavulanate based on infection site, local resistance, allergy history, dosing requirements and formulary position.
When did cefaclor lose exclusivity?
Cefaclor lost practical U.S. market exclusivity decades ago. The original product entered the market in 1979, and generic competition subsequently eliminated the commercial protection associated with the Ceclor brand.
Small-molecule antibiotics are not subject to the biologic exclusivity framework that applies to biosimilars. Any initial regulatory exclusivity associated with the original NDA has long expired. Current cefaclor competition is governed primarily by generic ANDA approvals, manufacturing capacity and reimbursement economics.
Cefaclor exclusivity timeline
| Event |
Approximate timing |
Commercial effect |
| Original U.S. approval of Ceclor |
1979 |
Eli Lilly commercialized cefaclor |
| Original compound and product protection |
Expired before the modern generic market |
Generic entry became possible |
| Generic cefaclor approvals |
Developed after innovator protection ended |
Price competition increased |
| Ceclor brand decline |
1990s-2000s |
Branded revenue contracted |
| Current market |
Generic-dominated |
Low average selling prices and fragmented supply |
Patent expiration dates for early cefaclor patents are no longer commercially material. The relevant question is not whether an active patent blocks generic entry, but whether manufacturers can maintain profitable supply under low reimbursement rates.
What patents protect cefaclor today?
No meaningful U.S. composition-of-matter patent protection remains for cefaclor. Current products are generally exposed to generic competition without a durable patent barrier.
The original cefaclor patent estate covered the active compound and related pharmaceutical chemistry. Those rights expired long ago. Formulation and dosage patents associated with extended-release products also do not create a current market-wide barrier comparable to an active new chemical entity patent.
Are cefaclor formulations protected by patents?
The principal formulation distinctions are:
- Immediate-release capsules
- Powder for oral suspension
- Extended-release tablets or capsules in selected markets
- Different strengths and pediatric concentrations
Formulation patents may have historically covered extended-release delivery systems, excipient combinations or manufacturing processes. Those rights do not protect the basic cefaclor market today. Generic manufacturers can compete through immediate-release products, and any remaining formulation-specific restrictions would affect only a narrow dosage-form segment.
The oral suspension category may have greater technical sensitivity than capsules because manufacturers must control particle size, stability, taste, reconstitution performance and antimicrobial preservation. These factors are manufacturing and regulatory barriers, not broad patent barriers.
What is the FDA regulatory status of cefaclor?
Cefaclor remains an FDA-recognized prescription antibiotic active ingredient, although the original Ceclor brand is not the principal source of current U.S. supply.
The FDA’s Orange Book identifies approved drug products and, where applicable, patents and regulatory exclusivity. For a mature generic such as cefaclor, the commercial market is generally based on abbreviated new drug applications rather than an active innovator franchise.[2]
FDA status by product category
| Product category |
Regulatory position |
| Cefaclor capsules |
Generic prescription products |
| Cefaclor oral suspension |
Generic prescription products |
| Ceclor branded products |
Legacy innovator products; commercial availability may vary |
| Extended-release cefaclor |
Limited market relevance compared with immediate-release forms |
| Injectable cefaclor |
Not a standard U.S. cefaclor market category |
| Biosimilar products |
Not applicable |
FDA labeling warns about beta-lactam hypersensitivity and other adverse reactions. As with other antibiotics, cefaclor prescribing is affected by antimicrobial stewardship and the risk of inappropriate use.[1]
How many patents cover cefaclor?
There is no commercially significant active U.S. patent estate covering the core cefaclor molecule. The number of historical patents is less important than the absence of a current blocking patent position for standard generic presentations.
A practical patent assessment is:
| Patent layer |
Current relevance |
| Cefaclor composition patent |
Expired |
| Original process patents |
Expired or commercially nonblocking |
| Immediate-release capsule patents |
No meaningful current barrier |
| Oral suspension patents |
Limited commercial relevance |
| Extended-release formulation patents |
Potentially relevant only to narrow dosage forms |
| Method-of-use patents |
No broad current barrier to standard antibacterial use |
| Manufacturing know-how |
Relevant to cost, quality and supply reliability |
Are there Paragraph IV challenges for cefaclor?
Paragraph IV litigation is not a central current market issue for standard cefaclor products. Paragraph IV certifications are most valuable when a listed patent can delay generic entry into a high-value market. Cefaclor lacks the revenue scale and active patent structure that typically support substantial patent litigation.
Any historical ANDA filings may have used patent certifications, but the economic effect has passed because generic cefaclor has already entered the market. Current commercial risk is more likely to involve supply interruption, FDA manufacturing actions, product recalls or contract losses than a new Paragraph IV challenge.
Which companies are challenging or competing with cefaclor?
Cefaclor competes mainly with other oral antibiotics rather than through direct branded patent challenges. Generic suppliers may change over time as companies enter or exit the market.
Direct and therapeutic competitors
| Competitor |
Competitive relationship |
| Cefalexin |
Lower-cost first-generation oral cephalosporin; often preferred for susceptible skin and soft-tissue infections |
| Cefuroxime axetil |
Oral second-generation cephalosporin with different spectrum and dosing profile |
| Cefpodoxime |
Oral third-generation cephalosporin used in selected indications |
| Amoxicillin-clavulanate |
Major broad-spectrum alternative in respiratory and other infections |
| Azithromycin |
Alternative in selected respiratory settings, subject to resistance considerations |
| Trimethoprim-sulfamethoxazole |
Alternative for specific infections and susceptibility profiles |
Cefaclor’s competitive position depends on local resistance, physician familiarity, payer formulary rules and the availability of lower-priced alternatives. It is not positioned as a premium antibiotic.
What generic entry risks exist for cefaclor?
Generic entry risk is already realized rather than prospective. Cefaclor has a mature generic market, so the central business risks are margin erosion and supply instability.
Key generic-market risks
- Price compression. Multiple suppliers can compete for pharmacy and wholesaler contracts, reducing average selling prices.
- Low-volume exits. Manufacturers may discontinue products when reimbursement no longer covers quality, regulatory and distribution costs.
- Supplier concentration. A small number of active manufacturers can create vulnerability if one facility experiences a shortage or inspection issue.
- Dosage-form imbalance. Capsules may have more suppliers than oral suspension, making pediatric presentations more exposed to shortages.
- Substitution. Clinicians can move patients to cefalexin, amoxicillin-clavulanate or other oral antibiotics.
- Antimicrobial stewardship. Hospitals and health systems increasingly restrict unnecessary broad-spectrum antibiotic use.
A generic entrant would face low patent risk but also limited pricing power. The business case would depend on manufacturing efficiency, reliable API procurement, stable FDA compliance and access to pharmacy or institutional contracts.
What is the financial trajectory for cefaclor?
Cefaclor’s financial trajectory is structurally mature to declining in branded terms and stable-to-declining in generic terms. It is unlikely to produce meaningful revenue growth without a new delivery format, geographic expansion or a supply disruption affecting competitors.
Revenue trajectory
| Period |
Financial profile |
| 1979-1980s |
High-value branded growth following launch |
| 1990s |
Mature branded product with expanding generic pressure |
| 2000s |
Major decline in branded economics; generic substitution increased |
| 2010s |
Low-price generic market with fragmented suppliers |
| 2020s |
Mature, low-growth product; value tied to supply continuity and selected markets |
Public company filings generally do not isolate cefaclor revenue because it is sold as part of broader generic portfolios. Product-level revenue estimates from commercial databases may differ substantially depending on whether they measure manufacturer sales, pharmacy spending, tender sales or retail prescriptions.
Financial drivers
Volume
Volume is supported by the continued use of oral antibiotics in outpatient care. It is constrained by:
- Generic alternatives with stronger prescribing familiarity
- Antibiotic resistance
- Treatment guidelines favoring narrower-spectrum drugs where appropriate
- Reduced use for viral respiratory illness
- Product discontinuations and formulary changes
Price
Pricing is low relative to patented or branded antibiotics. Price increases may occur during shortages, but they are difficult to sustain when alternative cephalosporins and penicillin-based antibiotics are available.
Gross margin
Generic margins depend on scale. Capsule production may be relatively straightforward, while oral suspension production requires additional controls for stability, flavoring, reconstitution and packaging. Smaller suppliers may face unfavorable economics even when demand remains steady.
Geographic mix
The United States is a mature generic market. Cefaclor may retain stronger relevance in selected international markets where prescribing practice, branded-generic competition and local manufacturing differ. Pricing and market access vary by country, and U.S. revenue assumptions should not be applied globally.
What manufacturing and intellectual-property barriers affect cefaclor?
Cefaclor has low intellectual-property barriers but moderate operational barriers.
Manufacturers must demonstrate identity, strength, purity, dissolution, stability and microbiological quality. Oral suspension products add requirements for particle uniformity, reconstitution, palatability and in-use stability. Beta-lactam manufacturing may require dedicated or segregated facilities to manage cross-contamination risk.
Manufacturing risk matrix
| Barrier |
Impact on market |
| API availability |
Can affect continuity and cost |
| Beta-lactam facility controls |
Raises compliance and capital requirements |
| FDA inspection status |
Can remove a supplier from the market |
| Suspension stability |
Limits reliable pediatric supply |
| Packaging and reconstitution performance |
Affects recalls and customer acceptance |
| Low reimbursement |
Reduces incentives for redundant capacity |
The combination of low selling prices and quality-system costs explains why older antibiotics can experience shortages even when the underlying chemistry is well established.
What patent litigation and settlement agreements affect cefaclor?
No current, high-value patent litigation is a defining feature of the cefaclor market. The commercial lifecycle is too mature for a conventional innovator-generic settlement to drive market timing.
Historical litigation, if any, would have centered on generic entry, formulation rights or manufacturing processes. Those disputes do not materially change the present U.S. market outlook. Settlement agreements are not a meaningful source of current cefaclor valuation.
What is the Orange Book status of cefaclor?
The Orange Book remains the relevant FDA reference for approved U.S. drug products, therapeutic equivalence and listed patents. Cefaclor should be evaluated product by product because approved dosage forms, marketing status and active manufacturers can change.[2]
For investment and licensing analysis, the key Orange Book conclusions are:
- Cefaclor is not protected by a current core composition patent.
- Generic substitution is the dominant U.S. commercial model.
- Patent-based launch delays are not the principal market variable.
- Product availability and therapeutic-equivalence listings matter more than exclusivity.
- A discontinued brand listing does not necessarily mean that generic cefaclor is unavailable.
How does cefaclor compare with cefalexin and cefuroxime?
| Factor |
Cefaclor |
Cefalexin |
Cefuroxime axetil |
| Generation |
Second |
First |
Second |
| Market maturity |
Very mature |
Very mature |
Mature |
| Patent barrier |
None of commercial importance |
None of commercial importance |
None of commercial importance for standard generic products |
| Typical commercial position |
Low-cost alternative |
Often lower-cost, high-volume alternative |
Broader branded and generic history |
| Pediatric use |
Oral suspension available |
Oral suspension available |
Suspension and tablets, depending on market |
| Growth outlook |
Flat to declining |
More durable volume in established uses |
Dependent on indications and pricing |
| Main risk |
Substitution and supply |
Price competition |
Competition and formulation economics |
Cefalexin often has stronger volume economics because of its established use in skin and soft-tissue infections and its lower-cost positioning. Cefuroxime may retain a role where its spectrum or dosing is preferred, but it also faces generic price pressure.
What generic launch scenarios are realistic?
A new cefaclor generic launch would most likely follow one of three paths:
Low-price retail launch
A manufacturer enters with immediate-release capsules and competes through wholesalers and pharmacy benefit channels. This path has low patent risk but limited margin and requires scale.
Pediatric-suspension niche
A supplier targets oral suspension availability, where fewer reliable manufacturers may operate. The opportunity is more dependent on supply shortages and contract access than on premium pricing.
International or tender-market launch
A manufacturer focuses on markets where cefaclor remains established or where government tenders reward dependable supply. This approach can generate volume but normally produces low unit prices.
An extended-release launch would face greater formulation and regulatory complexity without a clear premium market unless a specific country has meaningful unmet demand.
What is the biosimilar risk for cefaclor?
Biosimilar risk is not applicable. Cefaclor is a chemically synthesized small molecule, not a biologic. Competition occurs through generic drug applications and national equivalents, including ANDA-based products in the United States.
The relevant competitive risk is substitution by other antibiotics and new generic suppliers, not biosimilar entry.
Key Takeaways
- Cefaclor is a mature, generic-dominated oral antibiotic.
- The original Ceclor brand no longer provides a meaningful U.S. growth platform.
- Core composition and conventional formulation patent protection have expired.
- Paragraph IV litigation and patent settlements are not current market drivers.
- No biosimilar pathway applies.
- Financial performance depends on generic volume, low-cost production and supply reliability.
- Oral suspension may offer the clearest niche because it has greater manufacturing complexity and fewer dependable suppliers.
- Cefalexin, cefuroxime and amoxicillin-clavulanate impose sustained therapeutic and pricing pressure.
- Product-level revenue is generally not disclosed by public manufacturers.
- The most credible outlook is stable-to-declining revenue, with temporary upside possible during supply disruptions.
FAQs
Is cefaclor still sold in the United States?
Generic cefaclor products may remain available, but individual manufacturers, strengths and dosage forms can change. The original Ceclor brand is not the primary commercial source.
Can cefaclor be substituted automatically at the pharmacy?
Substitution depends on the specific FDA therapeutic-equivalence listing, state law, prescription requirements and the product dispensed. Pharmacists must follow applicable substitution rules.
Does cefaclor have a new-drug exclusivity period today?
No. Any original regulatory exclusivity associated with the innovator product expired decades ago.
Is cefaclor more profitable in oral suspension than capsules?
Potentially, but suspension products also carry higher stability, packaging and quality-control costs. Profitability depends on supply contracts, manufacturing scale and reimbursement.
Could cefaclor become a shortage-driven investment opportunity?
Only temporarily and selectively. A shortage can improve pricing, but substitution, regulatory intervention and new supply can quickly reduce the benefit. The product lacks the patent protection needed to sustain premium pricing.
References
-
U.S. Food and Drug Administration. (n.d.). Ceclor cefaclor prescribing information. FDA Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
-
National Library of Medicine. (n.d.). Cefaclor drug label information. DailyMed. https://dailymed.nlm.nih.gov/dailymed/
-
U.S. Food and Drug Administration. (2019). Antimicrobial stewardship in outpatient settings. https://www.fda.gov/consumers/consumer-updates/combating-antibiotic-resistance
-
U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application process. https://www.fda.gov/drugs/types-applications/abbreviated-new-drug-application-anda-generics
